NCT06354127View on ClinicalTrials.gov

DWP450 for Treating Moderate to Severe Glabellar Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

473

Participants

Timeline

Start Date

August 12, 2020

Primary Completion Date

November 24, 2020

Study Completion Date

January 25, 2021

Conditions
Moderate to Severe Glabellar Lines
Interventions
DRUG

DWP450

The test drug or control drug is injected on the day of administration.

DRUG

Botox®

The test drug or control drug is injected on the day of administration.

Trial Locations (1)

Unknown

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT06354127 - DWP450 for Treating Moderate to Severe Glabellar Lines | Biotech Hunter | Biotech Hunter